HIF1A and glioblastoma: Topotecan, a United States Food and Drug Administration-approved anti-glioblastoma drug, can reduce overall cell SUMOylation, CDK6, and HIF-1α levels and regulate the cell cycle, but the specific target is not clear (Zheng et al., 2020).